OBJECTIVE: Traumatic brain injury is one of the major causes of death and disability among young people. Methylphenidate, a neural stimulant and protective drug, which has been mainly used for childhood attention deficit/hyperactivity disorder, has shown some benefits in late psychosocial problems in patients with traumatic brain injury. Its effect on arousal and consciousness has been also revealed in the sub-acute phase of traumatic brain injury. We studied its effect on the acute phase of moderate and severe traumatic brain injury (TBI) in relation to the length of ICU and hospital admission. PATIENTS AND METHODS: Severely and moderately TBI patients (according to inclusion and exclusion criteria) were randomized to treatment and control groups. The treatment group received methylphenidate 0.3mg/kg per dose PO BID by the second day of admission until the time of discharge, and the control group received a placebo. Admission information and daily Glasgow Coma Scale (GCS) were recorded. Medical, surgical, and discharge plans for patients were determined by the attending physician, blinded to the study. RESULTS:Forty patients with severe TBI (GCS = 5-8) and 40 moderately TBI patients (GCS = 9-12) were randomly divided into treatment and control groups on the day of admission. In the severely TBI patients, both hospital and ICU length of stay, on average, were shorter in the treatment group compared with the control group. In the moderately TBI patients while ICU stay was shorter in the treatment group, there was no significant reduction of the period of hospitalization. CONCLUSION: There were no significant differences between the treatment and control groups in terms of age, sex, post resuscitation GCS, or brain CT scan findings, in either severely or moderately TBI patients. Methylphenidate was associated with reductions in ICU and hospital length of stay by 23% in severely TBI patients (P = 0.06 for ICU and P = 0.029 for hospital stay time). However, in the moderately TBI patients who received methylphenidate, there was 26% fall (P = 0.05) only in ICU length of stay.
RCT Entities:
OBJECTIVE:Traumatic brain injury is one of the major causes of death and disability among young people. Methylphenidate, a neural stimulant and protective drug, which has been mainly used for childhood attention deficit/hyperactivity disorder, has shown some benefits in late psychosocial problems in patients with traumatic brain injury. Its effect on arousal and consciousness has been also revealed in the sub-acute phase of traumatic brain injury. We studied its effect on the acute phase of moderate and severe traumatic brain injury (TBI) in relation to the length of ICU and hospital admission. PATIENTS AND METHODS: Severely and moderately TBIpatients (according to inclusion and exclusion criteria) were randomized to treatment and control groups. The treatment group received methylphenidate 0.3mg/kg per dose PO BID by the second day of admission until the time of discharge, and the control group received a placebo. Admission information and daily Glasgow Coma Scale (GCS) were recorded. Medical, surgical, and discharge plans for patients were determined by the attending physician, blinded to the study. RESULTS: Forty patients with severe TBI (GCS = 5-8) and 40 moderately TBIpatients (GCS = 9-12) were randomly divided into treatment and control groups on the day of admission. In the severely TBIpatients, both hospital and ICU length of stay, on average, were shorter in the treatment group compared with the control group. In the moderately TBIpatients while ICU stay was shorter in the treatment group, there was no significant reduction of the period of hospitalization. CONCLUSION: There were no significant differences between the treatment and control groups in terms of age, sex, post resuscitation GCS, or brain CT scan findings, in either severely or moderately TBIpatients. Methylphenidate was associated with reductions in ICU and hospital length of stay by 23% in severely TBIpatients (P = 0.06 for ICU and P = 0.029 for hospital stay time). However, in the moderately TBIpatients who received methylphenidate, there was 26% fall (P = 0.05) only in ICU length of stay.
Authors: Milap V Rakholia; Raj G Kumar; Byung-Mo Oh; Prerna R Ranganathan; Sarah L Berga; Patrick M Kochanek; Amy K Wagner Journal: J Neurotrauma Date: 2018-08-24 Impact factor: 5.269
Authors: Alexis Steinberg; Jon C Rittenberger; Maria Baldwin; John Faro; Alexandra Urban; Naoir Zaher; Clifton W Callaway; Jonathan Elmer Journal: Resuscitation Date: 2017-12-05 Impact factor: 5.262
Authors: Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer Journal: J Neurotrauma Date: 2014-01-15 Impact factor: 5.269
Authors: Megan E Barra; Saef Izzy; Aliyah Sarro-Schwartz; Ronald E Hirschberg; Nicole Mazwi; Brian L Edlow Journal: J Intensive Care Med Date: 2019-04-09 Impact factor: 3.510
Authors: Dhananjay R Namjoshi; Craig Good; Wai Hang Cheng; William Panenka; Darrin Richards; Peter A Cripton; Cheryl L Wellington Journal: Dis Model Mech Date: 2013-09-12 Impact factor: 5.758